Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) ...

Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...

This trial is looking at a new way of giving carboplatin chemotherapy called adaptive therapy. It is comparing this to having standard carboplatin chemotherapy for ovarian cancer. It is for women ...

March 12, 2026 7:30am EDT Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...

Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...

The European Commission (EC) on Friday approved Incyte’s Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...